186 related articles for article (PubMed ID: 33982336)
1. Two hepatectomy cases for initially unresectable hepatocellular carcinoma after achieving a radiological complete response to sequential therapy with lenvatinib and transcatheter arterial chemoembolization.
Endo K; Kuroda H; Abe T; Sato H; Kooka Y; Oikawa T; Sato A; Nishiya M; Sugai T; Takikawa Y
Hepatol Res; 2021 Oct; 51(10):1082-1086. PubMed ID: 33982336
[TBL] [Abstract][Full Text] [Related]
2. Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy.
Kuroda H; Oikawa T; Ninomiya M; Fujita M; Abe K; Okumoto K; Katsumi T; Sato W; Igarashi G; Iino C; Endo T; Tanabe N; Numao H; Fukuda S; Iijima K; Masamune A; Ohira H; Ueno Y; Takikawa Y
Liver Cancer; 2022 Jul; 11(4):383-396. PubMed ID: 35978602
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
[TBL] [Abstract][Full Text] [Related]
4. A case of complete response with rechallenge-lenvatinib plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma refractory to multiple molecular-targeted agent treatments.
Tomonari T; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Kawano Y; Okamoto K; Miyamoto H; Sato Y; Takayama T
Clin J Gastroenterol; 2023 Jun; 16(3):438-443. PubMed ID: 36856957
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
[TBL] [Abstract][Full Text] [Related]
6. Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports.
Tomonari T; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Okamoto K; Miyamoto H; Muguruma N; Saito Y; Imura S; Bando Y; Shimada M; Takayama T
Medicine (Baltimore); 2020 Oct; 99(42):e22782. PubMed ID: 33080748
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study.
Sun B; Zhang L; Sun T; Ren Y; Cao Y; Zhang W; Zhu L; Guo Y; Gui Y; Liu F; Chen L; Xiong F; Zheng C
Front Oncol; 2022; 12():982948. PubMed ID: 36172158
[TBL] [Abstract][Full Text] [Related]
8. Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma.
Mawatari S; Tamai T; Kumagai K; Saisyoji A; Muromachi K; Toyodome A; Taniyama O; Sakae H; Ijuin S; Tabu K; Oda K; Hiramine Y; Moriuchi A; Sakurai K; Kanmura S; Ido A
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551623
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of lenvatinib-transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospective study.
Oshita K; Kobayashi T; Namba Y; Fukuhara S; Matsubara K; Takei D; Nakano R; Okamoto W; Sakai H; Tanimine N; Nakahara T; Kuroda S; Tahara H; Ohira M; Kawaoka T; Ide K; Imamura M; Aikata H; Ohdan H
BMJ Open; 2023 Oct; 13(10):e073797. PubMed ID: 37798025
[TBL] [Abstract][Full Text] [Related]
10. Multimodal treatment involving molecular targeted agents and on-demand transcatheter arterial chemoembolization for advanced hepatocellular carcinoma: A case report and review of the literature.
Oura K; Takuma K; Nakahara M; Tadokoro T; Fujita K; Mimura S; Tani J; Morishita A; Kobara H; Masaki T
Mol Clin Oncol; 2021 Aug; 15(2):154. PubMed ID: 34178325
[TBL] [Abstract][Full Text] [Related]
11. Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy.
Sho T; Morikawa K; Kubo A; Tokuchi Y; Kitagataya T; Yamada R; Shigesawa T; Kimura M; Nakai M; Suda G; Natsuizaka M; Ogawa K; Sakamoto N
World J Gastrointest Oncol; 2021 Dec; 13(12):2076-2087. PubMed ID: 35070043
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Lenvatinib's Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma.
Amioka K; Kawaoka T; Kinami T; Yamasaki S; Kosaka M; Johira Y; Yano S; Naruto K; Ando Y; Fujii Y; Uchikawa S; Ono A; Yamauchi M; Imamura M; Kosaka Y; Ohya K; Mori N; Takaki S; Tsuji K; Masaki K; Honda Y; Kouno H; Kohno H; Morio K; Moriya T; Naeshiro N; Nonaka M; Aisaka Y; Azakami T; Hiramatsu A; Aikata H; Oka S
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291850
[TBL] [Abstract][Full Text] [Related]
13. Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma.
Kosaka Y; Kawaoka T; Kosaka M; Shirane Y; Miura R; Murakami S; Johira Y; Yano S; Amioka K; Naruto K; Ando Y; Kodama K; Uchikawa S; Fujino H; Ohno A; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Imamura M; Aikata H
Intern Med; 2023 Jun; 62(12):1771-1774. PubMed ID: 36328580
[TBL] [Abstract][Full Text] [Related]
14. Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma.
Takano M; Kokudo T; Miyazaki Y; Kageyama Y; Takahashi A; Amikura K; Sakamoto H
World J Gastroenterol; 2016 Nov; 22(42):9445-9450. PubMed ID: 27895433
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib for Hepatocellular Carcinoma: A Literature Review.
Hatanaka T; Naganuma A; Kakizaki S
Pharmaceuticals (Basel); 2021 Jan; 14(1):. PubMed ID: 33418941
[TBL] [Abstract][Full Text] [Related]
16. Complete response by patients with advanced hepatocellular carcinoma after combination immune/targeted therapy and transarterial chemoembolization: two case reports and literature review.
Nong X; Zhang YM; Liang JC; Xie JL; Zhang ZM
Transl Cancer Res; 2022 Aug; 11(8):2973-2984. PubMed ID: 36093545
[TBL] [Abstract][Full Text] [Related]
17. Conversion Hepatectomy for Huge Hepatocellular Carcinoma With Arterioportal Shunt After Chemoembolization and Lenvatinib Therapy.
Sato N; Beppu T; Kinoshita K; Yuki H; Suyama K; Chiyonaga S; Motohara T; Komohara Y; Hara A; Akahoshi S
Anticancer Res; 2019 Oct; 39(10):5695-5701. PubMed ID: 31570469
[TBL] [Abstract][Full Text] [Related]
18. Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports.
Tian Y; Jin W; Sun H; Jin D; Kang D; Li Z; Piao L
J Hepatocell Carcinoma; 2023; 10():1587-1593. PubMed ID: 37791067
[TBL] [Abstract][Full Text] [Related]
19. [Influence of different treatment modalities on survival of patients with two -stage resection of unresectable hepatocellular carcinoma].
Fan J; Wu Z; Tang Z
Zhonghua Wai Ke Za Zhi; 2001 Oct; 39(10):745-8. PubMed ID: 16201184
[TBL] [Abstract][Full Text] [Related]
20. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
